For older patients, toenail length can provide important insight into a patient's functional status.
At week 12, results showed 71% in the upadacitinib group had achieved ACR20, compared to 63% and 36% in the adalimumab and placebo groups, respectively.
The TAZPOWER study is a randomized, double-blind, placebo-controlled Phase 2/3 crossover study evaluating the safety and efficacy of elamipretide (daily subcutaneous injections) in 12 male patients (aged ≥12 years) with genetically-confirmed Barth syndrome.
By inhibiting the activation of myostatin, SRK-015 may promote a clinically meaningful increase in muscle mass and strength.
More emphasis should be placed on self-management, physical and psychological therapies for treating low back pain, rather than pharmacological or surgical treatments.
Data added to the labeling includes first-of-their-kind pharmacokinetic studies demonstrating negligible to low transfer of CIMZIA through placenta and minimal transfer to breast milk from mother to infant.
At the 43-month endpoint, a total of 60.7% (307/506) of the abaloparatide followed by alendronate group had ≥3% increase in bone mass at all 3 sites (P<0.0001) vs. 24% (121/505) of the placebo followed by alendronate group.
In clinical trials, treatment with Durolane resulted in greater reduction in Visual Analog Scale (VAS) pain scores at 3 and 6 months compared to Synvisc One (hylan G-F 20; Sanofi Genzyme) (P<0.001).
Findings do not support the current practice of off-label use of hydroxychloroquine for treating symptomatic hand osteoarthritis.
Taltz demonstrated a statistically significant improvement in the signs and symptoms of AS.
Healthcare providers should incorporate biosimilars, where appropriate, into their regimens to treat patients with rheumatic diseases.
Long-term ICS exposure at high doses was associated with a modest but significant increase in the risk of hip or upper extremity fractures.
There have been no deaths reported with the use of Limbrel.
CNTX-4975 works by targeting the capsaicin receptor (TRPV1) to selectively and rapidly inactivate the local pain fibers transmitting signals to the brain.
Thirty-three randomized trials (n=51,145) were identified that met the inclusion criteria.
The new PsA approval was based on data from the Phase 3 OPAL Broaden, OPAL Beyond, and OPAL Balance studies.
Ixifi is a chimeric human-murine monoclonal antibody (mAb) against tumor necrosis factor.
The use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) was associated with a reduced risk of myocardial infarction (MI) among patients with rheumatoid arthritis (RA).
Taltz may be administered alone or in combination with a conventional disease-modifying antirheumatic drug, such as methotrexate.
More than two-thirds (85%) of those on sedatives and narcotics reported being counseled by a provider on the possibility of impaired driving.
Their results found that 22-24% of the hip injection group had new osteonecrosis vs. 5-9% of the hip control group and to 5% of the shoulder injection group.
TRM-201 (rofecoxib) is a highly potent COX-2 selective non-steroidal anti-inflammatory drug (NSAID) with a well-established efficacy profile.
The FDA is continuing to investigate Primus Pharmaceuticals and the manufacturing process for Limbrel, and will share updates as they become available.
The primary outcome was development of rheumatoid arthritis.
Treatments for cervical dystonia include oral medications, botulinum toxin injections, surgery, and complementary therapies.
Zilretta is the first extended-release, intra-articular injection for OA knee pain.
The needle stays hidden during injection and a sensor can detect placement on skin. It also includes 3 difference injection speeds, a progress bar and a speaker.
The device has 14 pre-set therapy modes designed to block acute or chronic pain or to imitate exercise recovery, endurance and muscle strength.
The FDA required the Uloric drug manufacturer, Takeda Pharmaceuticals, to conduct this safety study when the medicine was approved in 2009.
Specific foods that were highlighted include dried plums, blueberries, pomegranates, whole grains, ginger, turmeric, specific oils, and teas; these foods were found to reduce inflammatory cytokines, joint stiffness, pain, and oxidative stress.
There are currently no DMOADs approved for use in OA. MIV-711 is a selective inhibitor of cathepsin K, which is the principal protease involved in breaking down collagen in bones and cartilage.
The FDA's expanded approvals were supported by data from two Phase 3 multicenter, randomized, double-blind, placebo-controlled studies (GO-VIBRANT and GO-ALIVE) that included >600 patients.
Study authors aimed to assess the pharmacokinetics, efficacy, immunogenicity, safety, and drug discontinuation after switching from infliximab (Remicade) to the biosimilar CT-P13 in 192 patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis in daily practice.
The expanded approval was supported by data from a Phase 3 study that evaluated the safety and efficacy of subcutaneous Stelara in adolescents aged ≥12 years.
The fixed-dose product combines lesinurad, a uric acid transporter 1 (URAT1) inhibitor, with allopurinol, a xanthine oxidase inhibitor in one tablet.
Phase 3 results found that Zilretta achieved statistically significant reductions on the Western Ontario and McMaster Universities Arthritis Index (WOMAC) sections for pain, stiffness and function compared to immediate-release TCA.
Noven announced that CombiPatch (estradiol/norethindrone acetate transdermal system) and Minivelle (estradiol transdermal system) are now readily available following a temporary product shortage.
The new labeling now recommends patients with severe renal impairment be limited to a dose of 40mg once daily.
The CRL indicated a request for additional clinical data in order to evaluate the safety of sirukumab in the treatment of RA.
"We expect to begin enrolling patients as early as December in a proof-of-concept Phase 2 study of omadacycline in uUTI, and an indication in this type of infection would broaden the opportunities for oral omadacycline in community-acquired infections," said Evan Loh, MD, COO and CMO of Paratek.
The authors reported that of the patients who continued taking adalimumab for ≥1 year, 67.0% were considered in low disease activity (LDA)/remission (CDAI ≥10).
ARCH (Active-contRolled FraCture Study in Postmenopausal Women with Osteoporosis at High Risk of Fracture) was a multicenter, international, randomized, double-blind, alendronate-controlled study (n=4,093) in postmenopausal women with osteoporosis at high risk for fracture based on previous fracture history.
The data showed a statistically significant fracture risk reduction through 3.5 years.
In clinical trials, treatment with Durolane effectively relieved pain and restored function for up to six months in patients with knee osteoarthritis.
At the study's end, 29% of participants were either unable to walk or had difficulty doing so.
An FDA inspection of the clinic found that adipose tissue was being processed into stromal vascular fraction (stem cells derived from body fat) which was then administered intravenously or directly into the spinal cord of patients.
This marks the second approval of a biosimilar for adalimumab.
This fixed-dose combination product combines lesinurad, a uric acid transporter 1 (URAT1) inhibitor, with allopurinol, a xanthine oxidase inhibitor in one tablet.
Researchers used claims data between 2004-2015 from a large commercial database to identify patients with psoriatic arthritis who were initiated on DMARDs.
Study authors sought to compare OTC lidocaine 3.6% with menthol 1.25% patches vs. Rx lidocaine 5% as well as to placebo.
Results showed a significant reduction in the risk for secondary vertebral fracture with all of the of anti-osteoporotic drugs (risk ratio [RR] 0.38-0.77).
The supplemental New Drug Applications (sNDAs) contained data from Phase 3 trials involving patients with psoriatic arthritis, including safety analyses from the larger tofacitinib clinical development program.
The Stimpod NMS460 includes a nerve-mapping pen-like probe which allows practitioners to locate nerves and evaluate the treatment progress.
Sirukumab, a human monoclonal IgG1 kappa antibody, works differently than current IL-6 inhibitors approved to treat RA by targeting the IL-6 cytokine vs. the IL-6 receptor.
Methotrexate works by inhibiting dihydrofolic acid reductase, which interferes with DNA synthesis, repair, and cellular replication.
Accidental dosing with Cyclobenzaprine HCl may potentially lead to life-threatening serotonin syndrome when the drug is taken in combination with selective serotonin reuptake inhibitors.
Recovered organisms included various Streptococcus, Actinomyces, Haemophilus, Neisseria species, among others; all of the pathogens isolated were oral flora. Two patients also exhibited Staphylococcus aureus bacteria in the blood.
Infliximab products work by neutralizing the biological activity of TNF-alpha by binding with high affinity to the soluble and transmembrane forms of TNF-alpha and inhibiting the binding of TNF-alpha with its receptors.
Dr. Pascale Richetta, head of bone and executive vice president, UCB, stated, "With all three pivotal romosozumab Phase 3 studies now included in the clinical evidence package, representing data from more than 11,000 patients, we are committed to bringing this important potential new treatment to those people living at risk of fragility fractures."
Octagam 10% is currently approved to treat chronic immune thrombocytopenic purpura (ITP) in adult patients. It is supplied as 2g, 5g, 10g, or 20g single-use bottles.
Results showed that after a mean follow-up of 1.32 years, there were 27 hip fractures in the alendronate group and 73 in the non-alendronate group; this corresponded to incident rates of 9.5 (95% CI, 6.5-13.9) and 27.2 (95% CI, 21.6-34.2) fractures per 1000 person-years, respectively.
A greater response to Orencia was observed in the trial regardless of prior anti-TNF treatment and other non-biologic DMARD therapy.
Results showed a statistically significantly, but not a clinically important, improvement in two of the trials which evaluated radiofrequency denervation for the sacroiliac joints (−0.71 (95% CI, −1.35 to −0.06) and a combination of the facet joints, sacroiliac joints or intervertebral disks (−0.99 (95% CI, −1.73 to −0.25) at 3 months.
The proposed indications are for the treatment of non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), granulomatosis with polyangiitis and microscopic polyangiitis.
Over the 2.2 years mean follow-up, the immediate ART arm demonstrated greater BMD declines vs. the deferred ART arm at the hip (-2.5% vs. -1.0%, 95% CI: -2.2 to -0.8; P<0.001) and at the spine (-1.9% vs. -0.4%, 95% CI: -2.2 to -1.0; P<0.001).
The researchers found that intensive electronics users had significantly more discomfort, and more severe discomfort, in their wrist and hand.
The results from the 12-week period show that both arms of upadacitinib treatment were superior in achieving ACR 20 (64% in 15mg arm, 66% in 30mg arm) vs. placebo (36%).
The authors concluded that "rheumatologists and other clinicians caring for patients with RA face a significant dilemma precisely because the options for care of pain remain problematic."
The FDA approval was based on data from a Phase 3, multi-center, prospective, double-blind, randomized, placebo-controlled study in 381 adults treated with Dysport 1000 Units, Dysport 1500 Units or placebo after a stroke or traumatic brain injury.
Currently, there is a global Phase 3 program comprised of 6 studies involving approximately 7,000 patients with OA, CLBP or cancer pain with inadequate treatment of pain with approved therapies.
The proportion of study patients with lower limb amputations were similar for Jardiance (1.9%) and placebo groups (1.8%).
The researchers aimed to evaluate the association between dietary vitamin D, omega-3 fatty acids, and treatment outcomes with DMARDs in patients with rheumatoid arthritis.
When lesinurad 400mg was added to febuxostat, significantly more patients achieved target sUA by Month 6 (76.1%; P<0.0001) vs. febuxostat alone (46.8%); however, this was not seen with adding lesinurad 200mg (56.6%; P=0.13).
The approval of the prefilled syringe was based on dosing, efficacy, and safety data of SC abatacept in JIA among patients aged 2-17 years with inadequate response to at least one nonbiologic or biologic DMARD (Study JIA-2).
The data showed sarcopenia was 4 times more prevalent for the high-risk alcohol drinking group vs. the low-risk alcohol drinking group (odds ratio 4.29, 95% CI: 1.87, 9.82).
Initially, the team attributed the muscle weakness to either HIV or drug-mediated myopathy but a muscle biopsy later revealed atrophy of type II fibers without necrosis or inflammation.
Accidental patient dosing with Zurampic can potentially cause adverse renal effects such as acute renal failure; this is more common if Zurampic is given alone without a xanthine oxidase inhibitor.
Kevzara (sarilumab) injection has been approved for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs.
In the study, Actemra given weekly and bi-weekly combined with a 6-month glucocorticoid regimen, more effectively sustained remission through Week 52 than placebo combined with a 26-week steroid taper and a 52-week steroid taper.
Five important differences were identified by AACE/ACE involving pharmacotherapy choice as well as treatment duration and reevaluation.
In preclinical studies, AMO-02 has shown efficacy in transgenic models and reversal of muscle cell differentiation deficits in ex vivo tissue samples.
The researchers found that at the end of the study, pain levels didn't differ significantly between the patient who received intra-articular triamcinolone or saline.
An anticipated Prescription Drug User Fee Act (PDUFA) action date of December 2017 has been set by the FDA for both Xeljanz sNDAs.
Previous research has demonstrated a link between statin use and use-related injury and arthropathies.
Abaloparatide is a parathyroid hormone related peptide [PTHrP(1-34)] analog which acts as an agonist at the PTH1 receptor (PTH1R). This results in activation of the cAMP signaling pathway in target cells.
Ilaris for Injection will be replaced by Ilaris Injection (solution) for subcutaneous use.
The FDA has accepted for review the resubmission of the Biologics License Application (BLA) for Kevzara (sarilumab; Regeneron and Sanofi) for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more disease modifying antirheumatic drugs.
Which cities report the highest physician compensation?
To date, there is no approved oral liquid formulation of methotrexate for pediatric patients who require body surface area (BSA) dosing or who have difficulty swallowing or cannot ingest tablets or those with needle-phobia.
The CHERISH study was a multicenter, randomized, double-blind, sham-procedure controlled study to evaluate the safety and efficacy of Spinraza in children with later-onset SMA (n=126) aged 2-12 years.
A biosimilar product must demonstrate no clinically meaningful differences in safety or efficacy from the reference product.
The researchers concluded that stimulant drug use may result in acute stimulant-induced tremor as well as long-term proprioceptive deficits in terms of arm-droop.
The data overall showed favorable ACR and EULAR response criteria, DAS28, and modified Sharp scores with anti-TNF agents + methotrexate, with no difference with HAQ and rates of adverse events between the treatment groups.
The NDA for baricitinib was submitted in January 2016 and a 3-month extension for time to review additional analyses was announced in January 2017.
In general, there was low quality evidence from three trials indicating no reduction in systolic (-6.2mmHg, 95% CI: -12.8 to 0.5) or diastolic (-3.9mmHg, 95% CI: -9.2 to 1.4) 24-hour ambulatory BP with uric acid lowering drugs vs. placebo.
The FDA approval was based on efficacy data of Ingrezza in a 6-week clinical study (n=234) of patients who received Ingrezza vs. placebo.
Researchers evaluated the incidences of adverse events in women who initially received placebo during the FREEDOM trial and then received denosumab for up to 3 years during the FREEDOM Extension trial.
The study met its primary endpoint of Xgeva non-inferiority versus zoledronic acid in delaying the time to first on-study SRE in multiple myeloma patients (HR=0.98, 95% CI: 0.85, 1.14; P=0.01).
"This has important ramifications for public health recommendations," said Christopher Gallagher, MD, professor and director of the Bone Metabolism Unit in the Division of Endocrinology of Creighton University School of Medicine.